Episode 416: PREMIUM – CABANA – Ablation vs meds for symptomatic atrial fibrillation
In episode 416, James and Mike talk about the recently released CABANA study, the largest and longest trial done on catheter ablation for symptomatic atrial fibrillation. We find that in general the ablation group had fewer negative clinical outcomes and an improved quality of life. At the end we briefly discuss a paper that evaluated the level of evidence that supports the ~ 6000 recommendations in the cardiology guidelines from ACC/AHA/ESC.
Show notes
1) Effect of Catheter Ablation vs Antiarrhythmic Drug Therapy on Mortality, Stroke, Bleeding, and Cardiac Arrest Among Patients With Atrial Fibrillation: The CABANA Randomized Clinical Trial
JAMA. 2019 Mar 15. doi: 10.1001/jama.2019.0693
2) Effect of Catheter Ablation vs Medical Therapy on Quality of Life Among Patients With Atrial Fibrillation The CABANA Randomized Clinical Trial
JAMA. 2019 Mar 15. doi: 10.1001/jama.2019.0692
3) Levels of Evidence Supporting American College of Cardiology/American Heart Association and European Society of Cardiology Guidelines, 2008-2018
JAMA. 2019 Mar 19;321(11):1069-1080. doi: 10.1001/jama.2019.1122
Listening to this episode is for premium podcast members only. If you already have a membership, login to your account. If you aren't yet a premium subscriber, sign up today!
